Type 2 Diabetes and Weight Loss

3min Snip

00:00

Play full episode

Summary

Transcript

Episode notes

Early clinical trial data showed that this treatment reduced body weight by up to around 15% after 12 weeks. Eli Lilly is conducting early stage clinical trials with drugs that target GIP alone, which Holst says will resolve the ongoing debate. Other gut hormones involved in appetite, such as peptide YY are being explored too.

A new generation of anti-obesity medications are displaying striking results: drastically diminishing weight, without the serious side effects of previous medications.

These drugs have raised hopes the weight can be pharmacologically altered in a safe way, but some researchers are concerned about the drugs' high cost, and that these medications could feed into some societies' obsessions with thinness.

This is an audio version of our Feature: The ‘breakthrough’ obesity drugs that have stunned researchers

Hosted on Acast. See acast.com/privacy for more information.